Overview

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
A study of TQ-B3139, inhibitor of ALK/C-Met tyrosine kinase, in patient with advanced cancer
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd